Fahr’s syndrome and idiopathic hypoparathyroidism – A case report

Dejan M. Marinković*, Tamara Dragović†, Saša Kiković*, Snežana Kuzmić Janković*, Zorana Djuran*, Zoran Hajduković†

*Clinic for Endocrinology, Military Medical Academy, Belgrade, Serbia; †Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia

Abstract

Introduction. Fahr’s syndrome is a rare, slowly progressive, neurodegenerative disorder characterized by extensive, bilateral, and symmetrical basal ganglia calcification. It is associated with neuropsychiatric manifestations and gradually progressive cognitive impairment. Fahr’s syndrome is the secondary form of brain calcification that is caused by various metabolic, infectious, or degenerative diseases.

Case report. We presented a middle-aged male with Fahr’s syndrome due to primary idiopathic hypoparathyroidism. Clinical diagnosis was based on signs and symptoms of hypocalcemia, progressive neuropsychiatric illnesses, laboratory evidence of hypoparathyroidism, and radiologic signs of calcifications in the basal ganglia. The patient improved after only a few days of intravenous rehydration and calcium substitution, followed by oral supplemental calcitriol.

Conclusion. Timely recognition of idiopathic and iatrogenic hypoparathyroidism allows appropriate treatment that can prevent the development and clinical manifestations of Fahr’s syndrome and potentially slow its progression.

Key words: neurodegenerative diseases; calcinosis; basal ganglia; hypoparathyroidism; comorbidity; diagnosis, differential; drug therapy.

Introduction

Fahr’s syndrome (FS) is a rare, chronic, slowly progressive, neurodegenerative disorder characterized by extensive bilateral, and symmetrical deposition of calcium in the basal ganglia, thalamus, cerebral cortex, dentate nucleus, cerebellum subcortical white matter, and hippocampus. Clinical manifestations occur typically in the fourth or fifth decade of age and usually includes neuropsychiatric manifestations with gradually progressive cognitive impairment. The onset of the disease is usually insidious and frequently is misdiagnosed as a dementia or psychiatric illness.
Fig. 1 – Electrocardiogram of a patient with Fahr's syndrome showing first degree atioventricular block and slow and prolonged depolarisation (PR interval 214 ms, QT interval over 466 ms).
On the basis of clinico-radiological and biochemical findings, diagnosis of primary HP and Fahr’s syndrome was suggested.

Immediately after admission to the clinic, the patient got intravenous rehydration, antibiotics and calcium infusion, followed by oral supplemental calcium and calcitriol. Parenteral anticoagulation therapy was also conducted, while thiazide diuretics were administered in order to diminish calciuria. Dominant neuropsychiatric signs were stopped by mild anxiolytic therapy. Gradually after two weeks, all laboratory tests, clinical signs, and electrocardiogram finding went back to normal (Figure 3). He was recommended to take lifelong calcium and calcitriol substitution. Ambulatory, a 6-month control, evidenced maintaining of good general condition without any neurological symptoms or mental disorder. Serum calcium and ionized calcium levels were held at the lower reference limits.
Discussion

Basal ganglia calcification (BGC) is a nonspecific finding in 1% of radiographic brain examination \(^1,13,14\). These calcifications could be conditionally separated in two main forms: primary and secondary \(^3\).

The term Fahr’s disease refers to cases of idiopathic calcifications in the basal ganglia and other brain regions, and is clinically defined as bilateral BGC in the presence of neuropsychiatric and extrapyramidal disorders with normal calcium and parathyroid levels \(^4,12\). Fahr’s disease could be sporadic or inherited in an autosomal dominant pattern with the commonly involved locus at 14 q chromosome. Some form of this disease may also be passed on as an autosomal recessive trait \(^1,4,5,15,16\). This disease is also known as familial idiopathic basal ganglia calcifications; still there are 35 additional terms used for this condition in the literature. Some synonyms for this disease are: idiopathic striopallidodentate calcinosis, cerebrovascular ferro calcinosis, calcinosis nucleo-rum, familial idiopathic cerebral calcifications etc. \(^3,9\).

In contrast to this primary form, bilateral and symmetric calcifications of basal ganglia and other brain regions, can occur secondary, as the consequence of various metabolic, infectious, or degenerative disease. These includes endocrine disorders, mitochondrial myopathy, some dermatological disorders, brucellosis, toxoplasmosis, etc. \(^3,4,13\). This condition is known as Fahr’s syndrome. Clinically, it should be clearly distinguished from Fahr’s disease \(^3\).

Therefore, common for both conditions are bilateral BGC and progressive neuropsychiatric manifestations. The essential difference between the disease and the syndrome is the presence of the family history of BGC (Fahr’s disease) and evidence of some other, known cause (Fahr’s syndrome).

The most common reported metabolic disorders that cause Fahr’s syndrome are HP and pseudohypo-parathyroidism \(^1,17\). HP could be iatrogenic, as the consequence of surgical removal or radiotherapy, or could be idiopathic \(^1,6,13\). The latter refers to deficient PTH secretion without a defined cause and includes a group of rare conditions that can be genetically inherited and/or autoimmune. Inherited genetic HP may run in families by passing on with autosomal dominant, autosomal recessive or X-linked pattern, and may occur in childhood or later in life. Autoimmune HP may be isolated, or exist as a part of polyglandular syndrome such as autoimmune polyglandular syndrome type 1 or type 2. The former disorder is also inherited, but it usually occurs until the period of early adolescence and always by the age of 25. The latter presents in adulthood in combination with adrenal insufficiency, type 1 diabetes mellitus, or thyroid autoimmune diseases \(^2,5,13,18\). The most common cause of HP is damage or removal of the parathyroid glands during thyroidectomy \(^19,20\). In postoperative HP, basal ganglia calcifications will develop in untreated patients, after a median of 17 years \(^13,21\). Early treatment of postoperative HP can prevent brain calcifications with typical manifestations \(^6,10\). In patients with idiopathic form of HP, adequate oral calcitriol and calcium supplementation is needed in order to restore calcium/phosphorus ratio and reduce the risk of basal ganglia calcification appearance and progression \(^6,13,22\).

There is no clear explanation for the mechanism of brain calcification and hypocalcemia association. It is suggested that increased calcium-phosphorus complex formation plays an important role \(^6,13\). It is possible that the subsidence of calcium in the brain parenchyma, appear due to local disruption of the blood-brain barrier or due to a disorder of neuronal calcium metabolism. Active role of PTH in the basal ganglia physiology could also be involved. There are some findings that psychiatric conditions may be associated with calcium dysregulation, calcium signaling and altered calcium homeostasis \(^3,4\). Histological examination of affected areas revealed concentric calcium deposits within small and medium-sized arterial walls as well as droplet calcifications along capillaries \(^4\).

The most common clinical features are neurological as seizures, spasticity, choreoathetosis, tremor, headache, vertigo, dysthria, loss of consciousness. Psychiatric features include depression, manic symptoms, irritability, aggression, or deterioration of intelligence \(^1,3,4,16,18\). The impact of changes in calcium levels in the QT interval on ECG recording is well-known. In our case, electrocardiogram revealed episodes of sinus tachycardia with first degree AV block and prolonged depolarisation, fully retreated with normal serum calcium levels. Cardiac conduction disease were also observed in some cases of FD \(^23\).

In contrast to typical slowly progressive neuropsychiatric manifestations, in our case, all of the neurological symptoms occurred suddenly, and were provoked by respiratory infection. Polymorphic symptoms, including diffuse cramps, diarrhea, and body pain were non specific, while mental disorder and irritability were noticed only periodically. Other neurological manifestations, such as ataxia, adynamia, slurred speech, and mental confusion progressed rapidly in a few days. All of the symptoms related to hypocalcemia occurred in a short, 2-month interval, with no accompanied endocrine disorder, suggesting isolated idiopathic HP. Still, these symptoms were also the most prominent feature of clinical presentation in our patient, with positive Trouseau sign, decreased serum calcium, and PTH levels, followed by typical prolonged QT interval on electrocardiographic (ECG) examination. CT finding of bilateral brain calcifications completed the diagnosis towards Fahr’s syndrome due to HP.

To date, there is no standard course of treatment for Fahr’s syndrome/disease. A recent prospective study has found that increased risk for BGC progression is significantly associated with low calcium/phosphorus ratio, hyperphosphatemia and history of seizures \(^6,11\). Nevertheless, serum levels of 25(OH)D vitamin and 1.25 (OH)2D vitamin were not significantly associated with progression. Interestingly, with every 1% increase in the calcium/phosphorus ratio, progression of basal ganglia calcification decreased by 5% \(^6,13,19\).

Recommended treatment is directed toward symptomatic control of neurological manifestations using anxiolytics, antipsychotics, anticonvulsant treatment with appropriate rehydration, electrolyte, and hemodynamic balance maintenance \(^4,8,18\). In cases of Fahr’s syndrome due to hypoparathyroidism, the neurological and psychiatric
symptoms usually improve with normalisation of plasma calcium and phosphorus levels. It is recommended to obtain a target serum calcium level in the low normal range. HP is a rare endocrine condition with a hormone deficiency, that does not necessarily require the same substitution. The subcutaneous application of synthetic PTH analogs are recommended only in refractory forms with chronic hypercalciumia and kidney complications.

The presented patient showed no need for serious anti-convulsant or antipsychotic treatment. Dramatic clinical presentation and difficult general state of the presented patient was fully withdrawn after only a few days of intravenous rehydration and calcium substitution, followed with thiazide diuretics that reduced urinary loss of calcium. After achieving rapid resolution of symptoms, his treatment continued with oral supplemental calcium and calcitriol preparations for maintenance of serum calcium in the low to normal range.

Conclusion

Although rare, Fahr’s syndrome or/and Fahr’s disease are conditions that should be keep in mind in all the cases of progressive neuropsychiatric disturbances and seizure disorders, particularly if they are present in the fourth or fifth decade of age. In such cases, it is especially important to perform laboratory tests for the purpose of prompt registration of possible metabolic abnormalities. Any suspected hypoparathyroidism should be treated in time, especially in subjects that underwent thyroidectomy in order to prevent formation and progression of brain calcifications. On the other hand, every intracranial calcification, incidentally detected during radiographic imaging, needs thorough neurological examination and biochemical tests. Timely recognition of these two entities allows appropriate treatment that can prevent clinical manifestations of the disease and potentially slow its progression.

REFERENCES

10. Eaton LM, Camp JD, Lare JG. Symmetric cerebral calcification, particularly of basal ganglia, demonstrable roentgenographically; calcific ation of the finer cerebral blood vessels. Arch Neurol Psychiatr 1939; 41: 921–2.

Received on September 16, 2015. Revised on October 26, 2015. Accepted on November 3, 2015.

Online First May, 2016.